Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer.

Martínez-Bosch N, Guerrero PE, Moreno M, José A, Iglesias M, Munné-Collado J, Anta H, Gibert J, Orozco CA, Vinaixa J, Fillat C, Viñals F, Navarro P.

Oncotarget. 2016 Jul 26;7(30):48265-48279. doi: 10.18632/oncotarget.10199.

2.

Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.

Awasthi N, Zhang C, Schwarz AM, Hinz S, Schwarz MA, Schwarz RE.

Mol Cancer Ther. 2014 May;13(5):1032-43. doi: 10.1158/1535-7163.MCT-13-0361.

3.

Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.

Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE.

PLoS One. 2012;7(6):e38477. doi: 10.1371/journal.pone.0038477.

4.

Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells.

Makhov PB, Golovine K, Kutikov A, Teper E, Canter DJ, Simhan J, Uzzo RG, Kolenko VM.

Mol Cancer Ther. 2012 Jul;11(7):1510-7. doi: 10.1158/1535-7163.MCT-11-0907.

5.

Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.

Mahalingam D, Espitia CM, Medina EC, Esquivel JA 2nd, Kelly KR, Bearss D, Choy G, Taverna P, Carew JS, Giles FJ, Nawrocki ST.

Br J Cancer. 2011 Nov 8;105(10):1563-73. doi: 10.1038/bjc.2011.426.

6.

Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model.

Avella DM, Li G, Schell TD, Liu D, Zhang SS, Lou X, Berg A, Kimchi ET, Tagaram HR, Yang Q, Shereef S, Garcia LS, Kester M, Isom HC, Rountree CB, Staveley-O'Carroll KF.

Hepatology. 2012 Jan;55(1):141-52. doi: 10.1002/hep.24652.

7.

Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.

Awasthi N, Schwarz MA, Schwarz RE.

HPB (Oxford). 2011 Sep;13(9):597-604. doi: 10.1111/j.1477-2574.2011.00333.x.

8.

Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.

Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H.

Cancer Res. 2009 Mar 15;69(6):2506-13. doi: 10.1158/0008-5472.CAN-08-4323.

9.

Heterogeneity of kinase inhibitor resistance mechanisms in GIST.

Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, Fletcher CD, Corless CL, Fletcher JA.

J Pathol. 2008 Sep;216(1):64-74. doi: 10.1002/path.2382.

Supplemental Content

Support Center